While RAC1 and RAC1B have not been investigated specifically in the context of cetuximab resistance in CRC, RAC1 and RAC1B biology and signaling pathways suggest that their overexpression could contribute to cetuximab resistance, presenting a new target for combination therapy. This evidence concerns the gene RAC1 and colorectal carcinoma.